Next Phase Newsletter

A venture capital firm headquartered in Taiwan is focused on investing in tech-related companies such as AI, biotechnology, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S.

The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data.

The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An angel syndicate firm founded in 2022 and located in US has a tight focus on life science tools and biotech infrastructure with U.S. companies in Pre-Seed to Series A stages. The firm also has a select set of LPs where half are operators within life science tools. The firm can co-invest but prefers to lead investments with typical check sizes ranging from $160k-2M. The firm brings a fundamental understanding of life science in order to work with founders to build companies and pair them with capital. The firm is thesis-driven and can leverage their knowledgeable operator network, commercial reach, and M&A experience to accelerate company strategy.

The firm will only look into life science tools/software, SaaS serving life science, and medical device companies. The firm does not invest in therapeutics, diagnostics, or digital health. The firm is open to all stages of development and all classes of tools, software, and devices.

The firm will only work with companies whose founders and team members are 100% invested and requires that at least one academic founder works full time in the company. The firm prefers to take a board seat if (1) they lead the round and (2) it makes sense for the stage of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the US looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.
The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment arm of a leading conglomerate in Asia invests across public, private, and mezzanine asset classes across various industries, including life sciences and healthcare. The firm is stage agnostic, but has invested in pre-Series A and Series A rounds and has an increased interest in early-stage technologies. Investments can be made out of the firms’ proprietary capital or through special purpose vehicles (SPVs). The firm is interested in global opportunities. 
 
The firm is interested in all healthcare verticals: therapeutics, life science tools and diagnostics, medical devices, and digital health.  Within therapeutics, the firm is open to all types of modalities, indications, and therapeutic classes. The firm is stage agnostic and has invested in all rounds from pre-A to crossover rounds. 
 
The firm has no specific company or management requirements. The firm can act as either lead or co-investor. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A Venture Capital firm in the US currently investing out of its fourth fund looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor. 
 
The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data. 
 
The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring it’s investment to fund clinical trials and regulatory approval. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

A life sciences venture capital firm with offices in USA and Canada has invested in over 100 companies across multiple funds. The firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months, and prioritizes investment opportunities that are based in USA or Canada, though they will consider opportunities beyond.  
 
The firm invests primarily in therapeutics and medical devices, and consumer health technologies. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data. That said, the firm is open to earlier stage, pre-clinical companies with strong validation. The firm is agnostic in terms of modalities. 
 
The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Aa venture capital firm headquartered in the US is self-described as a thesis-driven earliest stage firm and looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund and primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America. 
 
The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases. 
 
The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.